Management Team
Min Wang Irwin
Dr. Min Wang Irwin is the co-founder and CEO of Reistone. She has 25 years of experiences in clinical development and medical affairs, working for top multinational pharma companies in the US, Canada and China.
Prior to Reistone, Dr. Min Irwin was formerly a venture partner at Qiming Venture Capital. During the early stages of her career, Dr. Irwin had led several global clinical trials, before taking up executive positions within Bayer, GlaxoSmithKline and Takeda as VP, head of clinical development and medical affairs in China and AP. She has built and led whole development teams of >200 people composed of clinical physicians, operation, project management, regulatory affairs, drug safety, and medical information as well medical affairs. Under Dr. Min Irwin leadership, over 20 new drugs and indications in China and Canada were successfully approved.
Dr. Min Irwin received her Medical degree and Master degree from the Third Military Medical University in China and Ph.D. in Clinical Biochemistry from University of Toronto.